Sunitinib
FDA Approved
Contents
Description
Sunitinib is a tyrosine kinase inhibitor used in the treatment of renal cell carcinoma. It works by blocking several protein kinases, preventing tumor growth and angiogenesis.
Indications & Therapeutic Use
Renal cell carcinoma, gastrointestinal stromal tumor, pancreatic neuroendocrine tumors
Linked Diseases:
renal cell carcinoma
C64D002292
Global Availability (5 countries)
| Country | Access Route | Regulatory Pathway | Lead Time | Status |
|---|---|---|---|---|
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — |
Buy / Source Sunitinib — GNH India
326 matching products available through GNH India. Select a product to view details and request a quote on the GNH India website.
Egotux
EU
Klertis
EU
Lusmose
EU
Mitant 25mg
25mgcapsuleIndia
Mitant 50mg
50mgcapsuleIndia
SANDOZ SUNITINIB
12.5 MGcapsuleCANADA
Subinit
EU
Suganet
EU
Products and ordering are fulfilled by GNH India. You will be redirected to www.gnhindia.com.
Available Through
This drug is available for procurement through the following fulfilment partner.
Fulfilment Partner
Sunitinib
| Generic Name | Sunitinib |
| Brands | 1 brand available |
| Active Ingredient | Sunitinib malate |
| Drug Class | Renal cell carcinoma |
| Manufacturer | Pfizer |
| Dosage Forms | Oral capsule |
| Medical Code | L01XE04 |
| Orphan Status | No |
| Cold Chain | Not Required |
| Reg. Status | FDA Approved |
| Countries | 5 countries |
Authority Signals
Last Verified3/21/2026
Data ConfidenceHigh (AI + Pharmacist)
Source Citations6 Validated Nodes